Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia.

Ferreira JJ, Bhidayasiri R, Colosimo C, Marti MJ, Zakine B, Maisonobe P.

Funct Neurol. 2012 Oct-Dec;27(4):225-30.

2.

Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia.

Ferreira JJ, Colosimo C, Bhidayasiri R, Marti MJ, Maisonobe P, Om S.

Parkinsonism Relat Disord. 2015 Feb;21(2):111-5. doi: 10.1016/j.parkreldis.2014.09.034. Epub 2014 Nov 20.

PMID:
25499753
3.

Ptosis as a remote effect of therapeutic botulinum toxin B injection.

Racette BA, Lopate G, Good L, Sagitto S, Perlmutter JS.

Neurology. 2002 Nov 12;59(9):1445-7.

PMID:
12427903
4.

BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).

Truong DD, Cullis PA, O'Brien CF, Koller M, Villegas TP, Wallace JD.

Mov Disord. 1997 Sep;12(5):772-5.

PMID:
9380065
5.

Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.

Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M.

Neurology. 1999 Oct 22;53(7):1431-8.

PMID:
10534247
6.

Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.

Pappert EJ, Germanson T; Myobloc/Neurobloc European Cervical Dystonia Study Group.

Mov Disord. 2008 Mar 15;23(4):510-7.

PMID:
18098274
7.

Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.

Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M.

Neurology. 1999 Oct 22;53(7):1439-46.

PMID:
10534248
8.

Botulinum toxin treatment of axial and cervical dystonia.

Benecke R, Dressler D.

Disabil Rehabil. 2007 Dec 15;29(23):1769-77. Review.

PMID:
18033602
9.

Botulinum toxin for the treatment of cervical dystonia.

Tintner R, Jankovic J.

Expert Opin Pharmacother. 2001 Dec;2(12):1985-94. Review.

PMID:
11825330
10.

Efficacy and safety of a new bulk toxin of botulinum toxin in cervical dystonia: a blinded evaluation.

Racette BA, McGee-Minnich L, Perlmutter JS.

Clin Neuropharmacol. 1999 Nov-Dec;22(6):337-9.

PMID:
10626093
11.

Botulinum toxin therapy for cervical dystonia.

Walker FO.

Phys Med Rehabil Clin N Am. 2003 Nov;14(4):749-66, vi. Review.

PMID:
14580035
12.

The safety and tolerability of botulinum toxins for the treatment of cervical dystonia.

Brashear A.

Expert Opin Drug Saf. 2005 Mar;4(2):241-9. Review.

PMID:
15794717
13.

Treatment of cervical dystonia with botulinum toxins.

Comella CL, Thompson PD.

Eur J Neurol. 2006 Feb;13 Suppl 1:16-20. Review.

PMID:
16417593
14.

Cervical dystonia: improved treatment response to botulinum toxin after referral to a tertiary centre and the use of polymyography.

Nijmeijer SW, Koelman JH, Standaar TS, Postma M, Tijssen MA.

Parkinsonism Relat Disord. 2013 May;19(5):533-8. doi: 10.1016/j.parkreldis.2013.01.018. Epub 2013 Mar 7.

15.

Xeomin in the treatment of cervical dystonia.

Benecke R.

Eur J Neurol. 2009 Dec;16 Suppl 2:6-10. doi: 10.1111/j.1468-1331.2009.02878.x.

PMID:
20002740
16.

Muscle selection for treatment of cervical dystonia with botulinum toxin--a systematic review.

Nijmeijer SW, Koelman JH, Kamphuis DJ, Tijssen MA.

Parkinsonism Relat Disord. 2012 Jul;18(6):731-6. doi: 10.1016/j.parkreldis.2012.04.005. Epub 2012 May 8. Review.

PMID:
22575237
17.

The position of the head in space: a kinematic analysis in patients with cervical dystonia treated with botulinum toxin.

Albani G, Bulgheroni MV, Mancini F, Mauro A, Fundarò C, Pacchetti C, Sandrini G, Nappi G.

Funct Neurol. 2001 Apr-Jun;16(2):135-41.

PMID:
11495419
18.

An open-label, sequential dose-escalation, safety, and tolerability study of rimabotulinumtoxinb in subjects with cervical dystonia.

Chinnapongse R, Pappert EJ, Evatt M, Freeman A, Birmingham W.

Int J Neurosci. 2010 Nov;120(11):703-10. doi: 10.3109/00207454.2010.515047.

PMID:
20942584
19.

[Dose-response relationship in the treatment of cervical dystonia with botulinum toxin type A (AGN 191622)--a phase II study].

Mezaki T, Kaji R, Kimura J, Mannen T.

No To Shinkei. 1995 Sep;47(9):857-62. Japanese.

PMID:
7546934
20.

Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.

Dressler D, Bigalke H, Benecke R.

J Neurol. 2003 Aug;250(8):967-9. Corrected and republished in: J Neurol. 2003 Oct;250(10):1263-5.

PMID:
12928917

Supplemental Content

Support Center